Trials / Unknown
UnknownNCT05673694
To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.
A Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EG017 in Androgen Receptor-positive, Estrogen Receptor-positive, and Human Epidermal Growth Factor Receptor-2-negative Patients With Advanced Breast Cancer.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety, tolerability, pharmacokinetics and efficacy of EG017 in androgen receptor-positive, estrogen receptor-positive, and human epidermal growth factor receptor-2-negative patients with advanced breast cancer.
Detailed description
The major aims of the study are to define the safety profile of this new drug, and to determine a recommended.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EG017 | According to the dosage group of the program, once a day. |
Timeline
- Start date
- 2023-03-08
- Primary completion
- 2025-11-07
- Completion
- 2026-01-02
- First posted
- 2023-01-06
- Last updated
- 2023-12-14
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05673694. Inclusion in this directory is not an endorsement.